Pfizer Inc. (PFE)

32.87
1.12 3.53
NYSE : Health Technology
Prev Close 31.75
Open 31.90
Day Low/High 31.75 / 33.00
52 Wk Low/High 27.88 / 44.56
Volume 25.77M
Avg Volume 31.93M
Exchange NYSE
Shares Outstanding 5.55B
Market Cap 181.07B
EPS 2.90
P/E Ratio 11.37
Div & Yield 1.52 (4.47%)

Latest News

Thank the Fed, Cessation of Economic Activity, Rescuing Airlines, 3 Key Stocks

Thank the Fed, Cessation of Economic Activity, Rescuing Airlines, 3 Key Stocks

When the central bank is on top of their game as they have been of late, credit must go where credit is due.

No Bottom Yet for Pfizer's Charts but We Have Price Targets to Watch

No Bottom Yet for Pfizer's Charts but We Have Price Targets to Watch

The daily trading volume has increased over the past two months telling us that PFE is not falling of its own weight but rather investors are voting with their feet.

Jim Cramer: Rate Cut No Cure for Coronavirus

Jim Cramer: Rate Cut No Cure for Coronavirus

But don't throw up your arms yet -- here are names that could be golden opportunities.

Pfizer Has an Attractive Dividend Yield, but What Do Its Charts Reveal?

Pfizer Has an Attractive Dividend Yield, but What Do Its Charts Reveal?

Here's how we would play shares of the pharmaceutical giant now.

Jim Cramer: Are These 10 High-Yielding Stocks on Your Radar?

Jim Cramer: Are These 10 High-Yielding Stocks on Your Radar?

These Dow stocks all yield above 3.3% right now, but are they worth the risk?

Shaky Markets, Economic Effects of Coronavirus, FOMC Meets, 3 Trading Thoughts

Shaky Markets, Economic Effects of Coronavirus, FOMC Meets, 3 Trading Thoughts

This coronavirus remains a China-centric problem? People are not yet dying in other countries. Do we have to worry here? That's the wrong question.

4 Favorite Biotech Stock Picks for 2020

4 Favorite Biotech Stock Picks for 2020

The Medical Technology Stock Letter's top pick rose 357% in 2019.

3 Sectors to Watch, First Quarter Volatility, 10 Dow Dogs: Market Recon

3 Sectors to Watch, First Quarter Volatility, 10 Dow Dogs: Market Recon

Also: People's Bank of China, the Fed, U.S./China trade deal, Brexit, USMCA.

Big Merger Monday Conjures Up Thoughts of Potential Biotech Targets

Big Merger Monday Conjures Up Thoughts of Potential Biotech Targets

The planned acquisition of The Medicines Company by Novartis spurs prospects of other deals in the drug business.

Jim Cramer: Drug Stocks Are Too Cheap

Jim Cramer: Drug Stocks Are Too Cheap

These stocks are priced for total imperfection. That's just what you want.

6 Market Winds of Change, Trading Beyond Meat, GrubHub Earnings: Market Recon

6 Market Winds of Change, Trading Beyond Meat, GrubHub Earnings: Market Recon

If there was not a sizable addressable market for Beyond Meat, the competition would not be building as quickly as it is.

Pfizer Upgraded to Hold at DZ Bank

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.

Pfizer Downgraded at Morgan Stanley

Trading Apple and Netflix, Beyond Meat Earnings: Market Recon

Trading Apple and Netflix, Beyond Meat Earnings: Market Recon

Overall, expect trading volume, with notable exception of action in specific names reporting earnings, to remain on the light side right through later Wednesday afternoon.

While No Magic Pill, Mylan Deal Might Just Revive Drugmaker

While No Magic Pill, Mylan Deal Might Just Revive Drugmaker

The merger with Pfizer's off-patent branded medicines business may be a life-preserver for bulls and provide meaningful expansion across geographical regions while leveraging Pfizer's commercialization capabilities.

A Look at Mylan's New Post-Merger Management

A Look at Mylan's New Post-Merger Management

What new management means for Mylan shareholders moving forward.

Financial Details for Pfizer on Mylan

Mylan Will Bounce Today and Become Stronger on the Short-Term Charts

Mylan Will Bounce Today and Become Stronger on the Short-Term Charts

Pfizer is in talks to merge its off-patent drug operation with Mylan.

Mylan Jumps on Deal With Pfizer to Form New Company

Mylan Jumps on Deal With Pfizer to Form New Company

Pfizer will combine its off-patent drug business with Mylan in the as-yet-to-be-named new company.

Jim Cramer: It's Looking Like the 1980s

Jim Cramer: It's Looking Like the 1980s

Kimberly-Clark's performance is nothing to sneeze at, and neither is Coca-Cola's, as higher sales, higher prices and big demand from emerging markets appear to give us a return to the good old days of great senior growth stocks.

Watch These 4 Japanese Drugmakers With Big Coming Events

Watch These 4 Japanese Drugmakers With Big Coming Events

Investors should keep tabs on these "focus events" from this quartet of U.S.-listed Japanese drugmakers that can make or break their treatments.

Buyout Speculation Picks Up in Biotech

Buyout Speculation Picks Up in Biotech

Here's my take on the M&A landscape as well as my own speculation of some possible logical buyout targets.

3 Autopilot Funds for a High-Yield Portfolio

3 Autopilot Funds for a High-Yield Portfolio

This portfolio is built to hold up in any market, throw off a steady 8% dividend and pay monthly dividends, to boot.

My 3 Predictions for the Second Half of 2019

My 3 Predictions for the Second Half of 2019

Watch the Russell 2000, housing activity, and mergers and acquisitions.

AbbVie's Allergan Deal Sets Up Another Trade In Big Biotech

AbbVie's Allergan Deal Sets Up Another Trade In Big Biotech

The drop in AbbVie's stock price following revelation of its plans to buy Allergan provides a way to hit a solid investment single using a buy-write options strategy.

Wall Street Voices Skepticism on AbbVie's Aggressive Allergan Acquisition

Wall Street Voices Skepticism on AbbVie's Aggressive Allergan Acquisition

Despite the financial positivity, many analysts warn the deal could have hiccups ahead.